105 related articles for article (PubMed ID: 34638348)
1. 1.5T Magnetic Resonance-Guided Stereotactic Body Radiotherapy for Localized Prostate Cancer: Preliminary Clinical Results of Clinician- and Patient-Reported Outcomes.
Poon DMC; Yuan J; Wong OL; Yang B; Chiu ST; Cheung KY; Chiu G; Yu SK
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638348
[TBL] [Abstract][Full Text] [Related]
2. A Prospective Study of Stereotactic Body Radiotherapy (SBRT) with Concomitant Whole-Pelvic Radiotherapy (WPRT) for High-Risk Localized Prostate Cancer Patients Using 1.5 Tesla Magnetic Resonance Guidance: The Preliminary Clinical Outcome.
Poon DMC; Yuan J; Yang B; Wong OL; Chiu ST; Chiu G; Cheung KY; Yu SK; Yung RWH
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884553
[TBL] [Abstract][Full Text] [Related]
3. A Prospective Single-Arm Phase 2 Study of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Prostate Cancer: Early Toxicity Results.
Bruynzeel AME; Tetar SU; Oei SS; Senan S; Haasbeek CJA; Spoelstra FOB; Piet AHM; Meijnen P; Bakker van der Jagt MAB; Fraikin T; Slotman BJ; van Moorselaar RJA; Lagerwaard FJ
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1086-1094. PubMed ID: 31419510
[TBL] [Abstract][Full Text] [Related]
4. One-year clinical outcomes of MR-guided stereotactic body radiation therapy with rectal spacer for patients with localized prostate cancer.
Poon DMC; Yuan J; Wong OL; Yang B; Tse MY; Lau KK; Chiu ST; Chiu PK; Ng CF; Chui KL; Kwong YM; Ma WK; Cheung KY; Chiu G; Yu SK
World J Urol; 2024 Feb; 42(1):97. PubMed ID: 38393414
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer - Acute toxicity and patient-reported outcomes in the prospective, multicenter
Fink CA; Ristau J; Buchele C; Klüter S; Liermann J; Hoegen-Saßmannshausen P; Sandrini E; Lentz-Hommertgen A; Baumann L; Andratschke N; Baumgartl M; Li M; Reiner M; Corradini S; Hörner-Rieber J; Bonekamp D; Schlemmer HP; Belka C; Guckenberger M; Debus J; Koerber SA
Clin Transl Radiat Oncol; 2024 May; 46():100771. PubMed ID: 38586081
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT).
Wolfe S; Diven MA; Marciscano AE; Zhou XK; Kishan AU; Steinberg ML; Miccio JA; Camilleri P; Nagar H
BMC Cancer; 2023 Sep; 23(1):923. PubMed ID: 37777738
[TBL] [Abstract][Full Text] [Related]
7. Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial.
Ma TM; Lamb JM; Casado M; Wang X; Basehart TV; Yang Y; Low D; Sheng K; Agazaryan N; Nickols NG; Cao M; Steinberg ML; Kishan AU
BMC Cancer; 2021 May; 21(1):538. PubMed ID: 33975579
[TBL] [Abstract][Full Text] [Related]
8. Magnetic Resonance-guided Stereotactic Radiotherapy for Localized Prostate Cancer: Final Results on Patient-reported Outcomes of a Prospective Phase 2 Study.
Tetar SU; Bruynzeel AME; Oei SS; Senan S; Fraikin T; Slotman BJ; Moorselaar RJAV; Lagerwaard FJ
Eur Urol Oncol; 2021 Aug; 4(4):628-634. PubMed ID: 32536573
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER).
Marciscano AE; Wolfe S; Zhou XK; Barbieri CE; Formenti SC; Hu JC; Molina AM; Nanus DM; Nauseef JT; Scherr DS; Sternberg CN; Tagawa ST; Nagar H
BMC Cancer; 2023 Aug; 23(1):781. PubMed ID: 37608258
[TBL] [Abstract][Full Text] [Related]
10. Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial.
Kishan AU; Ma TM; Lamb JM; Casado M; Wilhalme H; Low DA; Sheng K; Sharma S; Nickols NG; Pham J; Yang Y; Gao Y; Neylon J; Basehart V; Cao M; Steinberg ML
JAMA Oncol; 2023 Mar; 9(3):365-373. PubMed ID: 36633877
[TBL] [Abstract][Full Text] [Related]
11. The early result of whole pelvic radiotherapy and stereotactic body radiotherapy boost for high-risk localized prostate cancer.
Lin YW; Lin LC; Lin KL
Front Oncol; 2014; 4():278. PubMed ID: 25401085
[TBL] [Abstract][Full Text] [Related]
12. 1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment.
Alongi F; Rigo M; Figlia V; Cuccia F; Giaj-Levra N; Nicosia L; Ricchetti F; Sicignano G; De Simone A; Naccarato S; Ruggieri R; Mazzola R
Radiat Oncol; 2020 Mar; 15(1):69. PubMed ID: 32248826
[TBL] [Abstract][Full Text] [Related]
13. Analysis of online plan adaptation for 1.5T magnetic resonance-guided stereotactic body radiotherapy (MRgSBRT) of prostate cancer.
Poon DMC; Yang B; Geng H; Wong OL; Chiu ST; Cheung KY; Yu SK; Chiu G; Yuan J
J Cancer Res Clin Oncol; 2023 Feb; 149(2):841-850. PubMed ID: 35199189
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3)).
Janowski E; Chen LN; Kim JS; Lei S; Suy S; Collins B; Lynch J; Dritschilo A; Collins S
Radiat Oncol; 2014 Nov; 9():241. PubMed ID: 25398516
[TBL] [Abstract][Full Text] [Related]
15. Magnetic resonance guided SBRT reirradiation in locally recurrent prostate cancer: a multicentric retrospective analysis.
Boldrini L; Romano A; Chiloiro G; Corradini S; De Luca V; Verusio V; D'Aviero A; Castelluccia A; Alitto AR; Catucci F; Grimaldi G; Trapp C; Hörner-Rieber J; Marchesano D; Frascino V; Mattiucci GC; Valentini V; Gentile P; Gambacorta MA
Radiat Oncol; 2023 May; 18(1):84. PubMed ID: 37218005
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic Body Radiotherapy for Clinically Localized Prostate Cancer: Toxicity and Biochemical Disease-Free Outcomes from a Multi-Institutional Patient Registry.
Davis J; Sharma S; Shumway R; Perry D; Bydder S; Simpson CK; D'Ambrosio D
Cureus; 2015 Dec; 7(12):e395. PubMed ID: 26798571
[TBL] [Abstract][Full Text] [Related]
17. Five-Year Biochemical Results, Toxicity, and Patient-Reported Quality of Life After Delivery of Dose-Escalated Image Guided Proton Therapy for Prostate Cancer.
Bryant C; Smith TL; Henderson RH; Hoppe BS; Mendenhall WM; Nichols RC; Morris CG; Williams CR; Su Z; Li Z; Lee D; Mendenhall NP
Int J Radiat Oncol Biol Phys; 2016 May; 95(1):422-434. PubMed ID: 27084658
[TBL] [Abstract][Full Text] [Related]
18. 50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial.
Herrera FG; Valerio M; Berthold D; Tawadros T; Meuwly JY; Vallet V; Baumgartner P; Thierry AC; De Bari B; Jichlinski P; Kandalaft L; Coukos G; Harari A; Bourhis J
Int J Radiat Oncol Biol Phys; 2019 Feb; 103(2):320-334. PubMed ID: 30267761
[TBL] [Abstract][Full Text] [Related]
19. Magnetic Resonance-Guided Adaptive Radiation Therapy for Prostate Cancer: The First Results from the MOMENTUM study-An International Registry for the Evidence-Based Introduction of Magnetic Resonance-Guided Adaptive Radiation Therapy.
Teunissen FR; Willigenburg T; Tree AC; Hall WA; Choi SL; Choudhury A; Christodouleas JP; de Boer JCJ; de Groot-van Breugel EN; Kerkmeijer LGW; Pos FJ; Schytte T; Vesprini D; Verkooijen HM; van der Voort van Zyp JRN
Pract Radiat Oncol; 2023; 13(3):e261-e269. PubMed ID: 36462619
[TBL] [Abstract][Full Text] [Related]
20. Urinary Morbidity in Men Treated With Stereotactic Body Radiation Therapy (SBRT) for Localized Prostate Cancer Following Transurethral Resection of the Prostate (TURP).
Pepin A; Aghdam N; Shah S; Kataria S; Tsou H; Datta S; Danner M; Ayoob M; Yung T; Lei S; Gurka M; Collins BT; Krishnan P; Suy S; Hankins R; Lynch JH; Collins SP
Front Oncol; 2020; 10():555. PubMed ID: 32432033
[No Abstract] [Full Text] [Related]
[Next] [New Search]
